Gastrointestinal Intervention 2016; 5(3): 159-169
Published online October 31, 2016 https://doi.org/10.18528/gii150035
Copyright © International Journal of Gastrointestinal Intervention.
Gandhi Lanke1, Atin Agarwal2, and Jeffrey H. Lee1,*
1Department of Gastroenterology, Hepatology, and Nutrition, The University of Texas MD Anderson Cancer Center, Houston, TX, USA, 2Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Correspondence to:Department of Gastroenterology, Hepatology, and Nutrition, The University of Texas MD Anderson CancerCenter, 1515 Holcombe Blvd, Houston, TX 77030, USA.
This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Gastric cancer is the second leading cause of cancer related death in the world. In United States, gastric polyps are found in approximately 6% of upper endoscopy. The incidence of gastric polyps increased with widespread use of esophagogastroduodenoscopy and more liberal use of proton pump inhibitors. They are usually asymptomatic, but infrequently cause symptoms of bleeding, pain and gastric outlet obstruction. It is important to distinguish premalignant conditions and mimickers of malignancy.
Keywords: Carcinoid tumor, Endosonography,
Gastric polyps are found incidentally for an unrelated condition with increasing use of upper gastrointestinal endoscopy. Gastric polyps are either mucosal or submucosal and benign or malignant. They rarely cause symptoms. Management of gastric polyps is quite challenging. Early and accurate diagnosis and effective management may prevent the malignant transformation of these lesions, thus resulting in improved survival in some cases. This manuscript encompasses all types of gastric polyps we encounter in gastroenterology practice, providing the invaluable information regarding how to promptly make the diagnosis and manage them.
Proton pump inhibitors (PPI) are used more often than indicated, and there is concern about long term effects.1 They are overused because of over the counter availability and affordable cost. There is no consensus on the definition of duration of chronic use and while most agree that 4 to 12 months is considered a long term use.2 Both microscopic and macroscopic changes from proliferation in the mucosa of fundus and gastric body were described secondary to chronic PPI use. Microscopic changes like cystic gland formation, parietal cell hyperplasia, protrusion of parietal cells in to the oxyntic glands and macroscopic changes like formation of sporadic fundic polyps were described.1 In a retrospective study of 599 patients, of which 322 patients used PPI, the authors concluded that a long term use of PPI for 1 to 5 years was associated with fundic gland polyps (FGPs) when compared to less than 1 year (short term) use of PPI.3
They are the second most common gastric polyps (Fig. 1). They can be single, multiple, sessile, or pedunculated. They are composed of elongated and distorted pits lined by foveolar epithelium, inflamed and edematous lamina propria.4 They have a wide age range distribution and increases between ages of 60 to 80 years.5 The patient is commonly asymptomatic, but hyperplastic polyps can cause anemia, bleeding due to ulceration, dyspepsia, and gastric outlet obstruction.6,7 Although they are found most commonly in the antrum, they can be found anywhere in the stomach. Histologically, it shows dilated, marked elongation of the foveolae with branching, infiltrated by neutrophils, plasma cells, lymphocytes, mast cells, and macrophages resulting in corkscrew appearance.4 The stimuli for hyperplastic gastric polyps is not known but they are thought to arise from mucosal damage due to chronic inflammatory conditions leading to hyper regenerative epithelium. They are commonly encountered in the setting of
They occur predominantly in gastric fundus composed of normal gastric cell types (small glandular cell islands with parietal and chief cells) arranged in a disorderly or microcystic configuration (Fig. 2).13 They are more commonly seen in western countries because of the low prevalence of
These are mesenchymal tumors which arise from the subepithelial layers (muscularis mucosa or muscularis propria) of the gastrointestinal tract (Fig. 3). The etiology is not clear. The phenotypic resemblance to interstitial cells of cajal (ICCs) suggests that the origin is from ICCs.20 They can arise anywhere in the Gastrointestinal tract but the most common location is the stomach.21 They are more common in middle age and older individuals.22 Both familial and sporadic gastrointestinal stromal tumors (GISTs) are seen. Although familial and sporadic GISTs are indistinguishable both in phenotype and molecular features,23 familial GISTs are more predisposed to development of multiple gastric and small intestinal GIST. In GIST, there is an over-expression of c-KIT, a growth factor tyrosine-kinase receptor that is normally expressed in myenteric plexus of adult gastrointestinal tract, melanocytes, and hematopoietic stem cells.24 Conversely, in about 5% of GISTs, c-KIT is not expressed; however, mutation in platelet derived growth factor receptor-alpha (PDGFRA) is seen.25 Prognostic factors include size, location, and mitotic rate.26,27 Size less than 2 cm and origin in the stomach are favorable prognostic factors as the risk of malignancy is extremely low.28,29 Clinical symptoms depend on size and location of the tumor. Iron deficiency anemia, melena, and hematemesis are seen with ulcerated lesions. In larger tumors, abdominal pain and early satiety27 are present. The liver and peritoneum are the most common metastatic sites.
Histologically, they are spindle cells with elongated nuclei and eosinophilic cytoplasm arranged in whorls or short fascicles.30 Epithelioid type is seen in KIT negative GIST tumors that harbor PDGFRA mutation.31 Radiological features of GIST tumors vary depending on their size. Tumors larger than 2 cm develop focal ulceration of the underlying mucosa because of pressure necrosis which is referred to “bulls eye” on radiology.32 They tend to invade adjacent structures like the pancreas, colon and diaphragm with increase in size. Differential diagnosis for GIST includes schwannoma, leiomyoma, type 1 carcinoid, metastasis to the stomach from breast cancer and melanoma. Computed tomography (CT) with oral and intravenous contrast is the initial imaging of choice to characterize the mass, evaluate the extent and spread of tumor. It appears as smoothly contoured solid mass that enhances with intravenous contrast. On upper endoscopy both GIST and leiomyoma appear as a subepithelial mass with smooth margins and occasional ulceration. Endoscopic ultrasonography (EUS) can help differentiate subepithelial lesions based on the layer of origin and also in obtaining biopsy for cytological analysis and immunohistochemistry. Treatment for localized GIST is surgical resection if feasible. Although there are no clear guidelines, NCCN (National Comprehensive Cancer Network) recommends a follow-up with CT abdomen and pelvis, every 3 to 6 months for 3 to 5 years and then annually, for completely resected GIST tumors. For locally advanced or metastatic GIST tumors receiving imatinib, the patients should have a CT abdomen and pelvis every 3 to 6 months. Adjuvant therapy with imatinib is recommended for tumors greater than 3 cm in size or if the margins are positive after surgical resection. In addition, neoadjuvant therapy with imatinib is recommended for tumors that are unresectable, borderline resectable with locally advanced or tumors that require extensive organ disruption. The goal of neoadjuvant therapy is to reduce the tumor size thereby making it potentially resectable with organ preservation.
They are polypoid, circumscribed lesions lined by dysplastic epithelium composed of either tubular and or villous structures (Fig. 4). They account for 6% to 10% of gastric polyps in western populations.33 Atrophic gastritis and intestinal metaplasia are associated with the development of gastric adenoma.34 They may occur in individuals with familial adenomatous polyps and their incidence increases with age.35 They are frequently solitary and commonly found in the antrum. Histologically, they are classified into tubular, villous, or tubulovillous. Polyps that have villous histology and size greater than 2 cm have a 28% to 40% increased risk of malignancy.36 High grade dysplasia predisposes to invasive cancer, not only within the polyp but also in synchronous areas of the stomach.37 Differentiating between low and high dysplasia of gastric adenoma is based on degree of mitotic activity, cytoplasmic differentiation, nuclear crowding, hyperchromasia, stratification, and architectural distortion.38 Gastric adenomas may have combined gastric and intestinal features39 and minority of them contain foveolar or pyloric gland epithelium. The pyloric adenoma is more common in older patients (women > men) and carries a 30% risk of malignant transformation.40
Gastric neuroendocrine tumors (NETs) formerly known as carcinoids are well differentiated arising in the oxyntic mucosa of corpus or fundus composed of nonfunctioning enterochromaffin cells (Fig. 5). There are three types of carcinoid in the stomach. Type 1 carcinoids are most common and usually found in middle-aged women with autoimmune gastritis. The pathogenesis involves autoimmune destruction of parietal cells which leads to loss of feedback inhibition of gastrin and enterochromaffin cell proliferation appearing as small nodules in the body of the stomach.41 Type 2 carcinoids are rare and they occur in multiple endocrine neoplasia type 1 (MEN1), Zollinger-Ellison syndrome, or gastrin secreting tumors. They metastasize in approximately 30%42 of cases and have a worse prognosis compared to type 1 carcinoids. Treatment for type 2 involves evaluation for metastasis, resection of local tumor, and removal of gastrin secreting tumor. Type 3 carcinoids are usually solitary arising anywhere in the stomach and are sporadic. Lymph node metastasis is found in approximately 71% of cases measuring more than 2 cm and the treatment involves surgical resection.43
Symptoms include nonspecific epigastric pain or carcinoid syndrome caused by the release of histamine and tachykinin (flushing, lacrimation, facial edema, lacrimation, bronchoconstriction, and headache). A barium contrast study helps in identifying polypoid lesions and abdominal CT can assist in identifying lymph node spread and liver metastasis.44 Radiolabeled somatostatin analogues like pentatreotide are helpful in identifying local vs metastatic foci of carcinoid tumors having somatostatin receptors.45 Histolopathologically, they contain variety of cell types which include enterochromaffin like, enterochromaffin, and X cells.46 They are immunoreactive for synaptophysin, neuron specific enolase, and chromogranin; exhibit different growth patterns like trabecular, solid, rosette or combination of these types. Antrectomy is recommended for multiple lesions and for recurrence after removal since it decreases the stimulus for growth by removing hypergastrinemia.47 For sporadic lesions,
It is a diffuse type of gastric cancer characterized by diffuse thickening and it accounts for 3% to 19% of gastric adenocarcinoma (Fig. 6).50 Most are asymptomatic but symptoms arise at an advanced stage.51 Metastasis from breast should be excluded as infiltrative lobular cancer of breast tends to metastasize to the stomach, mimicking gastric linitis plastica (GLP).52 Common symptoms when present include early satiety, abdominal discomfort, weight loss, dysphagia, dyspepsia and vomiting.53 Often there is regurgitation of food into the esophagus because of infiltration of tumor cells decreasing the volume of stomach and hence interfering with peristalsis. Linitis plastica usually involves the lower third of the mucosa; thus and biopsy of mucosa can be negative because the mucosa is not infiltrated. Multiple biopsy samples from the same site or using diathermic snare can increase the yield of diagnosing GLP. Preoperative staging is important in the diagnosis and treatment. CT scan and gastroscopy are the two important tools in evaluating the extent of cancer. Histopathologically, GLP consists of atypical cells which often has a signet ring cell appearance and are diffusely infiltrating.54 CT scan findings include thickened stomach wall, diffuse gastric wall thickening, perigastric stranding, lung nodules, mediastinal lymphadenopathy, local lymphadenopathy and liver metastasis. Primary gastric adenocarcinoma has a low fluorodeoxyglucose (FDG) uptake because of non-intestinal type, signet ring cells, high mucous content, and low cellularity.55 For distant metastasis, the sensitivity and specificity of positron emission tomography (PET) are 35% to 74% and 74% to 99%, respectively.56 PET FDG activity of standardized uptake value less than 4 was reported not associated with esophagogastric neoplasia57 but associated with physiologic smooth muscle activity or non-neoplastic inflammation in the stomach. A complete preoperative staging is composed of diagnostic laparoscopy, CT, endoscopy, endoscopic ultrasound, and ultrasound abdomen. Serum tumor markers such as carcinoembryonic antigen, CA 19-9 and CA 72-4 are frequently done before treatment. Elevated CA 19-9 is elevated in patients with peritoneal spread and lymph node involvement and associated with a poor prognosis.58 Treatment is a complete resection, but only 20% of them benefit from total gastrectomy59 because peritoneal seeding, extension to surrounding organs and metastasis to lymph nodes is common. A role of postoperative radiation with or without chemotherapy should be further evaluated in future studies since complete resection is not possible in the majority of cases.
It is the most frequently encountered precancerous lesion of the stomach (Fig. 7).60 The sequence of gastric adenocarcinoma of intestinal type includes nonatrophic gastritis, multifocal atrophic gastritis, metaplasia, and dysplasia.61 It is more common in populations at high risk for gastric cancer, as in Eastern Asia, Eastern Europe, and Andean Latin America. In United States, high-risk populations include African Americans, Native Americans, and immigrants from Asia and Latin America.62 Risk factors for gastric intestinal metaplasia (GIM) include
In gastric cancer screening of high risk patients, pepsinogen was found to be useful as it is cost effective, less invasive, and provides faster results.68
It is helpful in preoperative staging of gastric cancer and also detection of both benign and malignant tumors. When compared to gastroscopy, it provides additional information not only about the gastric wall but also the entire abdomen.72 Multidetector CT allows three dimensional images and creates thinner or thicker sections in a shorter acquisition time.73 CT manifestation of gastric cancer can be a polypoid lesion, focal or diffuse (linitis plastica) mural thickening with or without ulceration. D’Elia et al74 evaluated the diagnostic accuracy of CT in preoperative staging of gastric cancer when compared to pathology. The diagnostic accuracy was 80% and 99% in an early and advanced gastric cancer respectively. Diagnostic accuracy of tumor stage was 78%; depth of invasion was 20% in early and 87% in advanced cancer. The sensitivity and specificity of liver metastasis were 87.5% and99%, respectively.
In another prospective study by Kim et al,75 they evaluated the diagnostic accuracy of multiplanar CT in preoperative staging of gastric cancer when compared to pathology. Both virtual endoscopy (volumetric CT) and transverse CT is used. Volumetric images give added advantage of endoluminal perspective when compared to transverse CT. For tumor stage, diagnostic accuracy for transverse CT vs volumetric CT were 77% vs 84%; for lymph node detection 62% vs 64%; and for metastasis 86% for both respectively.75 Kwee and Kwee76 reviewed five multidetector row CT studies for staging of gastric cancer and the overall accuracy for T-staging was 77.1% to 88.9%. Sensitivity and specificity for the serosa involvement were 82.8% to 100% and 80% to 96.8%, respectively.76
Binstock et al77 evaluated the radiologic features of carcinoid tumors in CT. Carcinoids can be detected as small submucosal or mucosal polyp in patients with history of chronic atrophic gastritis and hypergastrinemia. In patients with MEN1, they can be identified as multiple gastric polypoid masses and diffuse gastric wall thickening. In type 3 carcinoids, it can be seen with metastatic lymph node involvement of the liver, spleen, and perigastric region, and localized thickening of posterior gastric wall.77
Hyperplastic polyps on CT can be detected as multiple small, round, sessile polyps in fundus or gastric body and they usually range in 5 to 10 mm size. Gastric adenomas are usually solitary, found adjacent to the antrum; they are sessile or pedunculated and are lobulated in appearance, sometimes with size > 2 cm.
It is preferred over CT in renally compromised patients as gadolinium contrast is not nephrotoxic. It also has the advantage of no radiation. In a study of 189 patients, Jang et al78 compared the diagnostic accuracy of magnetic resonance imaging (MRI) vs two-dimensional CT for gastric cancer. They showed that the diagnostic accuracy and sensitivity of MRI (combined conventional, diffusion weighted) vs CT were 77.8% to 78.3% vs 67.7% to 71.4% and 75.3% to 75.9% vs 64.1% to 68.2%, respectively. The diagnostic accuracy and sensitivity for conventional MRI alone were 72% to 73% and 68.8% to 70%, respectively.78 In another study by Kim et al,79 the authors looked at 20 patients with gastric cancer and they compared MRI vs pathology to determine the accuracy of T-staging and N-staging. The accuracy of T-staging and N-staging for gastric cancer with MRI vs pathology were 74% and 47%, respectively.79 MRI has certain limitations stemming from its high cost, motion artifacts, and lack of stable contrast medium.80 Use of abdominal binders, antiperistalitic agents, phased-coil arrays, and breath-hold imaging techniques can reduce motion artifacts and improve the quality of images.81
In a prospective study involving 64 patients, Dromain et al82 evaluated the sensitivity of CT, MRI and somatostatin receptor scintigraphy (SRS) for the detection of liver metastasis from well differentiated gastroenteropancreatic tumors; the sensitivity of SRS, CT, and MRI were 49.3%, 78.5%, and 95.2%, respectively.82
18F-FDG PET is sensitive for NETs with high proliferation index when compared to low proliferation index.83 In a prospective study of 96 patients, Binderup et al84 compared the sensitivity of SRS with 111 In-Diethylenetriaminepentaacetic acid-octreotide, scintigraphy with 123I-metaiodobenzylguanidine (MIBG) and 18F-FDG PET for diagnosing NETs. The sensitivity of SRS, 123I-MIBG scintigraphy, and 18F-FDG PET were 89%, 52%, and 58%, respectively.84 In a study of 124 patients investigating the sensitivity and positive predictive value of 18F-FDG PET for screening early gastric cancer (EGC) in Japan, the authors found the sensitivity 37.9% and specificity 33.6%.85
Probe-based confocal laser microscopy (pCLE) has an advantage over high definition white light endoscopy (WLE) and chromo endoscopy in identifying mucosal dysplasia and EGC by direct histological visualization of the tissue, thus allowing targeted biopsy.86 There are 2 types of CLE, endoscopy-based CLE (eCLE) and pCLE. While pCLE is convenient to use through the endoscopes, eCLE may provide a higher resolution and deeper depth penetration when compared to pCLE. In a prospective study of 46 patients, the authors reported that the accuracy of pCLE, conventional endoscopic biopsy, combined pCLE and conventional endoscopic biopsy for diagnosis of early gastric adenocarcinoma were 91.7%, 85.2%, and 98.1%, respectively.87 In another prospective study of 182 patients, the sensitivity, specificity, positive predictive value, negative predictive value and accuracy of CLE for detection of superficial gastric cancer when compared to white-light endoscopy were found to be 88.9% vs 72.2%, 99.3% vs 95.1%, 85.3% vs 41.6%, 99.5% vs 98.6%, and 98.1% vs 94.1%, respectively.88
Narrow band imaging (NBI) provides clear images of microvasculature and gastrointestinal mucosa and can enhance early detection of gastric cancer. In a retrospective study of 51 patients, Horiuchi et al89 looked at the sensitivity and specificity of detection of coexistence of gastric cancer in hyperplastic gastric polyps with WLE and magnifying endoscopy-NBI (ME-NBI). The sensitivity and specificity for WLE were 66.7% and 96.2%, respectively. The sensitivity and specificity of ME-NBI were 83.3% and 84.6% for fine mucosal structure, and 54.5% and 92.3% for irregularity of micro vessels, respectively.89 In a retrospective study of 99 patients, the sensitivity, specificity, diagnostic accuracy of NBI vs chromoendoscopy for gastric cancer smaller than 5 mm in size were found to be 78% vs 43.7%, 92.9% vs 81.6%, 88.3% vs 69.9%, respectively.90
It enhances tumor localization and characterization by application of various dyes. Absorptive, contrast, and reactive stains are different types of stains used. Absorptive stains include methylene blue and Lugol’s iodine that are useful in detecting gastric metaplasia and EGC. Reactive stains like congo red and phenol help in detection of gastric cancer and
Hyperplastic polyps are usually less than 1 cm, smooth, domeshaped, or stalked. Endoscopic finding of white opaque substance in a gastric hyperplastic polyp is suggestive of neoplastic transformation.94 There are no endoscopic guidelines for follow up of hyperplastic gastric polyp without dysplasia, but, if polyp persists or dysplasia is present, polypectomy is recommended with repeat EGD in one year.41 Whenever hyperplastic polyps are seen, examination of the whole stomach should be made to look for mucosal abnormalities and biopsy should be done to look for a synchronous cancer.95 There are no standard guidelines for endoscopic removal of hyperplastic polyps. Although polyps greater than 2 cm should be removed,96 carcinoma can arise in polyps smaller than 2 cm.97 When hyperplastic polyps arise from chronic atrophic gastritis, the severity should be assessed based on the Operative Link for Gastritis Assessment (OLGA) or the Operative Link on Gastritis/Intestinal Metaplasia Assessment staging systems.98 In general, 5 to 7 biopsy specimens (3 from the antrum, 2 from the lesser curvature of corpus and 2 from the greater curvature of the corpus) should be obtained to assess the severity of atrophic gastritis. Endoscopic surveillance should be considered for stage 3 or stage 4 OLGA but the guidelines are not standardized.
Gastric adenomas range in size from few millimeters to 4 cm in size99 and are flat or sessile. Endoscopic follow-up for gastric adenoma should be done 6 months after incomplete polypectomy or for high grade dysplasia and 1 year for all other polyps.41 High grade dysplasia predisposes to invasive cancer not only within the polyp but also in synchronous areas of the stomach.37 Operative resection should be considered for those not amenable for endoscopic resection.
Gastric NETs on upper gastrointestinal endoscopy are visible as submucosal masses that have yellow color, small, and rounded.100 For type 1 and type 2 carcinoids measuring less than 1 cm and fewer than 3 to 5 in number, endoscopic polypectomy with follow-up every 6 months is recommended.101
Endoscopic features of GLP include prominent gastric folds, thickened area of irregular gastric mucosa at greater curvature, circumferential thickening of the proximal stomach, fungating lesion extending form the esophagogastric junction to the antrum and diffuse gastric mucosal inflammation with normal biopsy.
As aforementioned, GIM is classified histologically into complete and incomplete intestinal types. Incomplete IM should undergo endoscopic mapping to identify multifocal areas of IM because several studies showed progression of IM to gastric adeno carcinoma.102 Typically, biopsies are obtained from the antrum, corpus, incisura angularis, and any visible lesions.103 For complete IM, endoscopic surveillance is not indicated unless there are other risk factors for gastric cancer.
EUS can help in differentiating submucosal and mucosal gastric polyps.104 It also helps in determining the feasibility of endoscopic resection by assessing the depth of involvement. In general, endoscopic resection is not indicated if it involves muscularis propria.105,106 EUS can further differentiate submucosal tumors from extrinsic compressions and cystic from solid masses.107 Carcinoids usually arise from deep mucosal or submucosal layers and spread deeper to submucosal area. While performing endoscopy, resection can be performed for type 1 and type 2 gastric carcinoids measuring 1 to 2 cm and confined within the mucosa and submucosal layers.108 However, for gastric carcinoids > 2 cm, surgical resection should be considered109–113 rather than endoscopic attempt. EUS can also help in identifying the blood vessel near the carcinoid, which can potentially help prevent bleeding during endoscopic resection.114
One of the indications for endoscopic mucosal resection (EMR) and ESD is curative resection of the EGC. Gastric lesions confined to the mucosa, papillary or tubular (differentiated) adenocarcinoma, less than 2 cm for elevated lesions, less than 1 cm for flat or depressed lesions, no venous or lymph node involvement, no ulcer or ulcer scar are ideal candidates for EMR.115 Identifying lymph node metastasis is important prior to attempting EMR or ESD. Paris and Kudo classifications describe shape and pit-pattern of the lesions. Paris 1 incudes protruded lesions; Paris 2 is subdivided into 2a slightly elevated, 2b completely flat, 2c depressed lesions; and Paris 3 lesions have ulceration in the mucosa.116 According to pit-patterns, Kudos classification is subdivided into type 1 (round), type 2 (stellar or papillary) which are nonneoplastic, type 3 (tubular or small roundish), type 4 (branch-like or gyrus-like), and type 5 (irregular or nonstructural pits) neoplastic.117 Type 5 usually involves the submucosal layer and portends higher lymph node metastasis.118 ESD has the advantage of
EMR is recommended for both type 1 and type 2 gastric carcinoids associated with hypergastrinemia, less than 1 cm in diameter and presence of 3 to 5 tumors.121 EUS is performed before treatment to assess the depth of invasion. Tumors confined to submucosa are treated endoscopically (EMR) and with deeper invasion are treated surgically. Endoscopic surveillance with bio-spy at 6 months interval is performed after complete resection to evaluate for recurrence.
Gastric adenoma (low grade dysplasia and high grade dysplasia) can progress to invasive carcinoma122 or advanced cancer123 at the time of follow-up. Treatment for gastric adenoma is endoscopic
Perforation with ESD (1.2%–5.2%) usually occurs in the upper and middle parts of the stomach because of the thin wall and ret-ro flexion position of the endoscope. The risk for perforation further increases with increasing size of the lesion and ulceration.126 Submucosal injection is paramount of importance in creating a safety net in ESD by providing an adequate space for dissection between the mucosa and muscularis propria layers. Single-closure and omental patch using endoclips are utilized in endoscopic closure. Single-closure is used for smaller defects and omental patch is used for larger defects.127 Bleeding can be immediate (intraoperative) or delayed (within 24 hours of procedure). For the control of bleeding, there are many in the armamentarium, electric cautery, injection therapy, placement of hemoclips, or combinations thereof. However, delayed bleeding can be prevented by carefully inspecting the resection bed and applying coagulation to the visible vessels while performing EMR or ESD.128 Stenosis usually occurs when the mucosal defect is greater than 75% of the circumference and/or longitudinal defect is more than 5 cm; a serial dilation with balloon inflation is often required to treat the stenosis.
With increasing incidence of gastric lesions detected, the prompt differentiation between benign from malignant gastric lesions is essential to successful, efficient, and cost-effective management. Careful inspection and biopsy of the lesion and perhaps the surrounding mucosa will prevent missing hidden cancers. Clearly, accurate diagnosis and staging, complete resection, and meticulous follow-up are the principles in preventing invasive surgery and potentially improving survival. Good judgment of endoscopists and close collaboration with pathologists are priceless in this challenging endeavor.
© The Society of Gastrointestinal Intervention. Powered by INFOrang Co., Ltd.